
Sign up to save your podcasts
Or


https://www.nejm.org/doi/full/10.1056/NEJMoa2309002
In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir–ritonavir for 5 or 10 days did not significantly reduce the risk of symptomatic SARS-CoV-2 infection.
https://www.nejm.org/doi/full/10.1056/NEJMoa2309003
https://www.nejm.org/doi/full/10.1056/NEJMoa2118542
Pfizer has some serious problems! #pfizer
By Questioning Medicine4.9
7474 ratings
https://www.nejm.org/doi/full/10.1056/NEJMoa2309002
In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir–ritonavir for 5 or 10 days did not significantly reduce the risk of symptomatic SARS-CoV-2 infection.
https://www.nejm.org/doi/full/10.1056/NEJMoa2309003
https://www.nejm.org/doi/full/10.1056/NEJMoa2118542
Pfizer has some serious problems! #pfizer

7,595 Listeners

14,815 Listeners

136 Listeners

699 Listeners

497 Listeners

259 Listeners

2,442 Listeners

3,340 Listeners

56,489 Listeners

1,150 Listeners

28,407 Listeners

6,395 Listeners

372 Listeners

29,193 Listeners

1,307 Listeners